Practical Cardiovascular Medicine. Elias B. Hanna

intervention for ST-segment-elevation acute myocardial infarction: data from the French registry on Acute ST-eleva- tion Myocardial Infarction (FAST-MI). Circulation 2008; 118: 268–76.

      11 50. Morrison LJ, Verbeek PR, McDonald AC, et al. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. JAMA. 2000 May 24-31;283(20):2686-92.+ Also: Björklund E, Stenestrand U, Lindbäck J, et al. Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patients with ST-elevation myocardial infarction. Eur Heart J 2006; 27: 1146–52.

      12 51. Fosbol EL, Granger CB, Jollis JG, et al. The impact of a statewide pre-hospital STEMI strategy to bypass hospitals without percutaneous coronary intervention capability on treatment times. Circulation 2013; 127:604–612

      13 52. Bagai A, Jollis JG, Dauerman HL, et al Emergency department bypass for ST-segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: a report from the American Heart Association Mission: Lifeline program. Circulation 2013; 128(4):352–359.

      OAT and late presenters

      1 53. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006; 355: 2395–407.

      2 54. Menon V, Pearte CA, Buller CE, et al. Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time dependent: insights from Occluded Artery Trial. Eur Heart J 2009; 30: 183–91.

      3 55. Schdmig A, Mehilli J, Antoniucci D, et al.; Beyond 12 hours Reperfusion AlternatiVe Evaluation (BRAVE-2) Trial Investigators. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA 2005; 293: 2865–72. In this study, late reperfusion 12–48 h improved LV infarct size. ~50% of these patients had subtotal occlusion, mostly with TIMI 2–3 flow.

      4 56. Busk M, Kaltoft A, Nielsen SS, et al. Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for <12 h vs. 12–72 h. Eur Heart J 2009; 30: 1322–30. When the infarct artery is patent (TIMI 1–3), late presenters >12 h derive the same percent salvage of the infracted territory as early presenters <12 h.

      5 57. Sim DS, Jeong MH, Ahn Y, et al. Benefit of percutaneous coronary intervention in early latecomers with acute ST-segment elevation myocardial infarction. Am J Cardiol 2012; 110: 1275–81.

      6 58. Udelson JE, Pearte CA, Kimmelstiel CD, et al. The occluded artery trial (OAT) viability ancillary study (OAT-NUC): impact of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone. Am Heart J 2011; 161: 611–21.

      7 59. Erne P, Schoenenberger AW, Burchkardt D, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction. The SWISSI 2 randomized controlled trial. JAMA 2007; 297: 1985–91.

      PCI flow

      1 60. Montalescot G, Barragan P, Wittenberg O; ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895–903.

      2 61. Stone G.W., Grines C.L., Cox D.A.; CADILLAC Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957–66.

      3 62. Stone GW, Witzenbichler B., Guagliumi G., et al.; HORIZONS-AMI Trial Investigators Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009: 360: 1946–59.

      4 63. Jolly SS, Cairns JA, Yusuf S, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 2015; 372: 1389–98. TOTAL trial. In contrast to the TAPAS trial, the TASTE and TOTAL trials did not show any clinical benefit of the routine use of thrombectomy.

      5 64. Gibson CM, Cannon CP, Murphy SA, et al.; TIMI Study Group. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percu- taneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002; 105: 1909–13.

      6 65. Sorajja P, Gersh BJ, Costantini C, et al. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 2005; 26: 667–74.

      7 66. Marshall JC, Waxman HL, Sauerwein A. Frequency of low-grade residual coronary stenosis after thrombolysis during acute myocardial infarction. Am J Cardiol 1990; 66: 773–8.

      8 67. Holmes D, Lerman A, Moreno PR, et al. Diagnosis and management of STEMI arising from plaque erosion. JACC Cardiovasc Imaging 2013; 6: 290–6.

      Multivessel CAD, PCI, and CABG in STEMI

      1 68. Goldstein JA, Demetriou D, Grines CL, et al. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000; 343: 915–22.

      2 69. Thiele H, Akin I, Sandri M,et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med. 2017;377:2419–2432. CULPRIT-SHOCK

      3 70. Mehta SR, Wood DA, Storey RF, et al. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med 2019; 381:1411–1421.

      4 71. Wald DS, Morris JK, Wald NJ, et al. PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 2013; 369(12):1115–1123.

      5 72. Engstrom T,Kelbaek H,Helqvist S, et al. Complete revascularization versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open label, randomized controlled trial. Lancet 2015; 386: 665–671.

      6 73. Hochman JS, Sleeper LA, Webb JG, et al.; Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) Investigators. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999; 341: 625–34. SHOCK trial.

      7 74. Crossman AW, D’Agostino HJ, Geraci SA. Timing of coronary artery bypass graft surgery following acute myocardial infarction: a critical literature review. Clin Cardiol 2002; 25: 406–10.

      Antithrombotics

      1 75. Dörler J, Edlinger M, Alber HF, et al. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Eur Heart J. 2011;32(23):2954–61.

      2 76. Montalescot G, van‘t Hof AW, Lapostolle F, et al; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371(11):1016–27.

      3 77. Erlinge D, Omerovic E, Fröbert O, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med. 2017;377(12):1132-1142. (VALIDATE-SWEDEHEART).

      4 78. Stone GW, Witzenbichler B, Godlewski J, et al. Intralesional abciximab and thrombus aspiration in patients with large anterior myocardial infarction: one-year results from the INFUSE-AMI trial. Circ Cardiovasc Interv 2013; 6: 527–34.

      5 79. COMMIT collaborative group. Addition of clopidogrel to ASA in 45,852 patients with acute myocardial infarction: randomized placebo controlled trial. COMMIT. Lancet 2005; 366: 1607–21.

      6 80. Sabatine MS, Cannon CP, Gibson CM, et al, for the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocar- dial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179–89.

      7 81. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006; 295: 1519–30.

      8 82. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated